iododoxorubicin

Iododoxorubicin is a halogenated small molecule derivative of the anthracycline doxorubicin, characterized by the substitution of a hydroxyl group with an iodine atom at the 4' position of the daunosamine sugar. This modification enhances its lipophilicity and reduces cardiotoxicity compared to parent anthracyclines. Originally developed as an antineoplastic agent that intercalates with DNA to inhibit cell proliferation, iododoxorubicin was later discovered to possess potent anti-amyloidogenic properties. It binds to and interferes with the formation and stability of amyloid fibrils, including those associated with AL amyloidosis (immunoglobulin light chains), AA amyloidosis, and beta-amyloid plaques in Alzheimer's disease. Clinical investigations have spanned oncology, where it showed limited activity in solid tumors like breast and colorectal cancer, and systemic amyloidosis, though its clinical use has largely been superseded by other treatments and structural analogs like doxycycline.

Other names

4'-deoxy-4'-iododoxorubicin4'-iodo-4'-deoxy-doxorubicin4'-iododeoxydoxorubicin4'-iododoxorubicin